Related Experiment Video
Updated: Mar 25, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Recently identified drug resistance biomarkers in ovarian cancer
Ben Davidson1,2
1a Department of Pathology , Oslo University Hospital, Norwegian Radium Hospital , Oslo , Norway.
Abstract:
Ovarian cancer, consisting mainly of ovarian carcinoma, is the most lethal gynecologic malignancy. Improvements in outcome for patients with advanced-stage disease are limited by intrinsic and acquired chemoresistance and by tumor heterogeneity at different anatomic sites and along disease progression. Molecules and cellular pathways mediating chemoresistance appear to be different for the different histological types of ovarian carcinoma, with most recent research focusing on serous and clear cell carcinoma. This review discusses recent data implicating various biomarkers in chemoresistance in this cancer, with focus on studies in which clinical specimens have been central.
Insights
Ovarian cancer chemoresistance limits treatment success. Biomarkers in clinical specimens offer insights into overcoming resistance in this lethal gynecologic malignancy.
Area of Science:
- Gynecologic Oncology
- Cancer Biology
- Translational Research
Background:
- Ovarian carcinoma is the leading cause of gynecologic cancer death.
- Chemoresistance and tumor heterogeneity impede treatment progress in advanced ovarian cancer.
- Histological type influences chemoresistance mechanisms, with focus on serous and clear cell subtypes.
Purpose of the Study:
- To review recent data on biomarkers associated with chemoresistance in ovarian cancer.
- To highlight the role of clinical specimens in understanding chemoresistance.
- To focus on advancements in serous and clear cell ovarian carcinoma research.
Main Methods:
- Literature review of recent studies.
- Analysis of data implicating biomarkers in chemoresistance.
- Emphasis on research utilizing clinical ovarian cancer specimens.
Main Results:
- Various biomarkers are implicated in mediating chemoresistance.
- Mechanisms of chemoresistance differ across ovarian carcinoma histological types.
- Clinical specimens are crucial for identifying relevant biomarkers and pathways.
Conclusions:
- Understanding biomarker roles is key to overcoming ovarian cancer chemoresistance.
- Targeting specific pathways based on histological type may improve patient outcomes.
- Further research using clinical specimens is essential for therapeutic development.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers